search
Back to results

Study of Irinotecan and Cetuximab Versus Irinotecan as Second-Line Treatment in Patients With Metastatic, EGFR-Positive Colorectal Cancer

Primary Purpose

Colorectal Cancer

Status
Completed
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
cetuximab
Irinotecan
Irinotecan
Sponsored by
Eli Lilly and Company
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Colorectal Cancer

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Histologically documented colorectal cancer which is EGFR-positive by immunohistochemistry [IHC] (may be based on archival samples) and is metastatic. Prior oxaliplatin administered for the first-line treatment of metastatic colorectal cancer. Prior fluoropyrimidine-containing regimen (5-fluorouracil [5-FU], capecitabine, or uracil/tegafur [UFT]), for the first-line treatment of metastatic disease. Exclusion Criteria: A serious uncontrolled medical disorder that, in the opinion of the Investigator, would impair the ability of the subject to receive protocol therapy Unresolved diarrhea, bowel obstruction, or history of inflammatory bowel disease Known or documented brain metastases

Sites / Locations

  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site
  • ImClone Investigational Site

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Arm A

Arm B

Arm Description

Outcomes

Primary Outcome Measures

Overall Survival

Secondary Outcome Measures

Progression Free Survival
Response
Duration of Response
Time to Response
Disease Control Rate
Safety
Quality of Life
Health Economics

Full Information

First Posted
June 20, 2003
Last Updated
April 8, 2010
Sponsor
Eli Lilly and Company
Collaborators
Bristol-Myers Squibb
search

1. Study Identification

Unique Protocol Identification Number
NCT00063141
Brief Title
Study of Irinotecan and Cetuximab Versus Irinotecan as Second-Line Treatment in Patients With Metastatic, EGFR-Positive Colorectal Cancer
Official Title
Revised Protocol 07 to Protocol CA225006 - A Phase III Randomized, Open-Label, Multicenter Study of Irinotecan and Cetuximab vs. Irinotecan as Second-Line Treatment in Patients With Metastatic, EGFR-Positive Colorectal Carcinoma
Study Type
Interventional

2. Study Status

Record Verification Date
April 2010
Overall Recruitment Status
Completed
Study Start Date
April 2003 (undefined)
Primary Completion Date
June 2006 (Actual)
Study Completion Date
October 2007 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
Eli Lilly and Company
Collaborators
Bristol-Myers Squibb

4. Oversight

5. Study Description

Brief Summary
The purpose of this study is to determine whether overall survival is prolonged in subjects with metastatic, epidermal growth factor receptor (EGFR)-positive colorectal cancer treated with cetuximab in combination with irinotecan compared with irinotecan alone as second-line therapy following treatment with a fluoropyrimidine and oxaliplatin based, non-irinotecan-containing regimen.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Colorectal Cancer

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
1302 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Arm A
Arm Type
Experimental
Arm Title
Arm B
Arm Type
Active Comparator
Intervention Type
Drug
Intervention Name(s)
cetuximab
Other Intervention Name(s)
Erbitux
Intervention Description
Vial, IV, 400 mg/m² week 1 then 250 mg/m², weekly, until PD/Toxicity/Pt-PI Decision
Intervention Type
Drug
Intervention Name(s)
Irinotecan
Intervention Description
Vial, IV, 350 mg/m², Q 3 Weeks, Until PD/Toxicity/Pt-PI Decision
Intervention Type
Drug
Intervention Name(s)
Irinotecan
Intervention Description
Vial, IV, 350 mg/m², Q 3 Weeks, Until PD/Toxicity/Pt-PI Decision
Primary Outcome Measure Information:
Title
Overall Survival
Time Frame
Every 3 months after subject off-treatment
Secondary Outcome Measure Information:
Title
Progression Free Survival
Time Frame
Q6 Weeks
Title
Response
Time Frame
Q6 Weeks
Title
Duration of Response
Time Frame
Q6 Weeks
Title
Time to Response
Time Frame
Q6 Weeks
Title
Disease Control Rate
Time Frame
Q6 Weeks
Title
Safety
Time Frame
Q3 Weeks
Title
Quality of Life
Time Frame
Q6 Weeks
Title
Health Economics
Time Frame
Q3 Weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Histologically documented colorectal cancer which is EGFR-positive by immunohistochemistry [IHC] (may be based on archival samples) and is metastatic. Prior oxaliplatin administered for the first-line treatment of metastatic colorectal cancer. Prior fluoropyrimidine-containing regimen (5-fluorouracil [5-FU], capecitabine, or uracil/tegafur [UFT]), for the first-line treatment of metastatic disease. Exclusion Criteria: A serious uncontrolled medical disorder that, in the opinion of the Investigator, would impair the ability of the subject to receive protocol therapy Unresolved diarrhea, bowel obstruction, or history of inflammatory bowel disease Known or documented brain metastases
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
E-mail: ClinicalTrials@ ImClone.com
Organizational Affiliation
Eli Lilly and Company
Official's Role
Study Chair
Facility Information:
Facility Name
ImClone Investigational Site
City
Tucson
State/Province
Arizona
ZIP/Postal Code
85712
Country
United States
Facility Name
ImClone Investigational Site
City
Pine Bluff
State/Province
Arkansas
ZIP/Postal Code
71603
Country
United States
Facility Name
ImClone Investigational Site
City
Bakersfield
State/Province
California
ZIP/Postal Code
93309
Country
United States
Facility Name
ImClone Investigational Site
City
Berkeley
State/Province
California
ZIP/Postal Code
94704
Country
United States
Facility Name
ImClone Investigational Site
City
Beverly Hills
State/Province
California
ZIP/Postal Code
90211
Country
United States
Facility Name
ImClone Investigational Site
City
Corona
State/Province
California
ZIP/Postal Code
92708
Country
United States
Facility Name
ImClone Investigational Site
City
Gilroy
State/Province
California
ZIP/Postal Code
95020
Country
United States
Facility Name
ImClone Investigational Site
City
Greenbrae
State/Province
California
ZIP/Postal Code
95904
Country
United States
Facility Name
ImClone Investigational Site
City
Long Beach
State/Province
California
ZIP/Postal Code
90813
Country
United States
Facility Name
ImClone Investigational Site
City
Los Angeles
State/Province
California
ZIP/Postal Code
90033
Country
United States
Facility Name
ImClone Investigational Site
City
Los Angeles
State/Province
California
ZIP/Postal Code
90057
Country
United States
Facility Name
ImClone Investigational Site
City
Montebello
State/Province
California
ZIP/Postal Code
90640
Country
United States
Facility Name
ImClone Investigational Site
City
Orange
State/Province
California
ZIP/Postal Code
92868
Country
United States
Facility Name
ImClone Investigational Site
City
Palm Springs
State/Province
California
ZIP/Postal Code
92262
Country
United States
Facility Name
ImClone Investigational Site
City
Rancho Mirage
State/Province
California
ZIP/Postal Code
92270
Country
United States
Facility Name
ImClone Investigational Site
City
San Diego
State/Province
California
ZIP/Postal Code
92120
Country
United States
Facility Name
ImClone Investigational Site
City
Stockton
State/Province
California
ZIP/Postal Code
95204
Country
United States
Facility Name
ImClone Investigational Site
City
Vallejo
State/Province
California
ZIP/Postal Code
94589
Country
United States
Facility Name
ImClone Investigational Site
City
Aurora
State/Province
Colorado
ZIP/Postal Code
80012
Country
United States
Facility Name
ImClone Investigational Site
City
Denver
State/Province
Colorado
ZIP/Postal Code
80218
Country
United States
Facility Name
ImClone Investigational Site
City
New Haven
State/Province
Connecticut
ZIP/Postal Code
06520
Country
United States
Facility Name
ImClone Investigational Site
City
New London
State/Province
Connecticut
ZIP/Postal Code
06320
Country
United States
Facility Name
ImClone Investigational Site
City
Norwich
State/Province
Connecticut
ZIP/Postal Code
06360
Country
United States
Facility Name
ImClone Investigational Site
City
Stamford
State/Province
Connecticut
ZIP/Postal Code
06902
Country
United States
Facility Name
ImClone Investigational Site
City
Fort Myers
State/Province
Florida
ZIP/Postal Code
33901
Country
United States
Facility Name
ImClone Investigational Site
City
Fort Myers
State/Province
Florida
ZIP/Postal Code
33990
Country
United States
Facility Name
ImClone Investigational Site
City
Inverness
State/Province
Florida
ZIP/Postal Code
34452
Country
United States
Facility Name
ImClone Investigational Site
City
Jacksonville
State/Province
Florida
ZIP/Postal Code
32207
Country
United States
Facility Name
ImClone Investigational Site
City
Jacksonville
State/Province
Florida
ZIP/Postal Code
32209
Country
United States
Facility Name
ImClone Investigational Site
City
Jacksonville
State/Province
Florida
ZIP/Postal Code
32224
Country
United States
Facility Name
ImClone Investigational Site
City
Lakeland
State/Province
Florida
ZIP/Postal Code
33805
Country
United States
Facility Name
ImClone Investigational Site
City
Miami
State/Province
Florida
ZIP/Postal Code
33136
Country
United States
Facility Name
ImClone Investigational Site
City
New Port Richey
State/Province
Florida
ZIP/Postal Code
34652
Country
United States
Facility Name
ImClone Investigational Site
City
Orlando
State/Province
Florida
ZIP/Postal Code
32806
Country
United States
Facility Name
ImClone Investigational Site
City
Port St. Lucie
State/Province
Florida
ZIP/Postal Code
34952
Country
United States
Facility Name
ImClone Investigational Site
City
Atlanta
State/Province
Georgia
ZIP/Postal Code
30309
Country
United States
Facility Name
ImClone Investigational Site
City
Atlanta
State/Province
Georgia
ZIP/Postal Code
30322
Country
United States
Facility Name
ImClone Investigational Site
City
Columbus
State/Province
Georgia
ZIP/Postal Code
31902-0951
Country
United States
Facility Name
ImClone Investigational Site
City
Macon
State/Province
Georgia
ZIP/Postal Code
31201
Country
United States
Facility Name
ImClone Investigational Site
City
Savannah
State/Province
Georgia
ZIP/Postal Code
31405
Country
United States
Facility Name
ImClone Investigational Site
City
Tucker
State/Province
Georgia
ZIP/Postal Code
30342
Country
United States
Facility Name
ImClone Investigational Site
City
Honolulu
State/Province
Hawaii
ZIP/Postal Code
96813
Country
United States
Facility Name
ImClone Investigational Site
City
Naperville
State/Province
Illinois
ZIP/Postal Code
60540
Country
United States
Facility Name
ImClone Investigational Site
City
South Bend
State/Province
Indiana
ZIP/Postal Code
46601
Country
United States
Facility Name
ImClone Investigational Site
City
Kansas City
State/Province
Kansas
ZIP/Postal Code
66160
Country
United States
Facility Name
ImClone Investigational Site
City
Overland Park
State/Province
Kansas
ZIP/Postal Code
66214
Country
United States
Facility Name
ImClone Investigational Site
City
Lexington
State/Province
Kentucky
ZIP/Postal Code
40536-0098
Country
United States
Facility Name
ImClone Investigational Site
City
Louisville
State/Province
Kentucky
ZIP/Postal Code
40202
Country
United States
Facility Name
ImClone Investigational Site
City
Richmond
State/Province
Kentucky
ZIP/Postal Code
40475
Country
United States
Facility Name
ImClone Investigational Site
City
Baton Rouge
State/Province
Louisiana
ZIP/Postal Code
70808
Country
United States
Facility Name
ImClone Investigational Site
City
Lafayette
State/Province
Louisiana
ZIP/Postal Code
70506
Country
United States
Facility Name
ImClone Investigational Site
City
Metairie
State/Province
Louisiana
ZIP/Postal Code
70006
Country
United States
Facility Name
ImClone Investigational Site
City
Shreveport
State/Province
Louisiana
ZIP/Postal Code
71103
Country
United States
Facility Name
ImClone Investigational Site
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
21204
Country
United States
Facility Name
ImClone Investigational Site
City
Frederick
State/Province
Maryland
ZIP/Postal Code
21701
Country
United States
Facility Name
ImClone Investigational Site
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02135
Country
United States
Facility Name
ImClone Investigational Site
City
Ann Arbor
State/Province
Michigan
ZIP/Postal Code
48106
Country
United States
Facility Name
ImClone Investigational Site
City
Detroit
State/Province
Michigan
ZIP/Postal Code
48201
Country
United States
Facility Name
ImClone Investigational Site
City
Southfield
State/Province
Michigan
ZIP/Postal Code
48075
Country
United States
Facility Name
ImClone Investigational Site
City
Minneapolis
State/Province
Minnesota
ZIP/Postal Code
55407-3799
Country
United States
Facility Name
ImClone Investigational Site
City
Robbinsdale
State/Province
Minnesota
ZIP/Postal Code
55422
Country
United States
Facility Name
ImClone Investigational Site
City
St. Louis Park
State/Province
Minnesota
ZIP/Postal Code
55426
Country
United States
Facility Name
ImClone Investigational Site
City
Jackson
State/Province
Mississippi
ZIP/Postal Code
39202
Country
United States
Facility Name
ImClone Investigational Site
City
Kansas City
State/Province
Missouri
ZIP/Postal Code
64111
Country
United States
Facility Name
ImClone Investigational Site
City
Rolla
State/Province
Missouri
ZIP/Postal Code
65401
Country
United States
Facility Name
ImClone Investigational Site
City
St. Louis
State/Province
Missouri
ZIP/Postal Code
63110
Country
United States
Facility Name
ImClone Investigational Site
City
Trenton
State/Province
New Jersey
ZIP/Postal Code
08690
Country
United States
Facility Name
ImClone Investigational Site
City
Voorhees
State/Province
New Jersey
ZIP/Postal Code
08084
Country
United States
Facility Name
ImClone Investigational Site
City
Albany
State/Province
New York
ZIP/Postal Code
12208
Country
United States
Facility Name
ImClone Investigational Site
City
Bronx
State/Province
New York
ZIP/Postal Code
10466
Country
United States
Facility Name
ImClone Investigational Site
City
East Setauket
State/Province
New York
ZIP/Postal Code
11733
Country
United States
Facility Name
ImClone Investigational Site
City
Latham
State/Province
New York
ZIP/Postal Code
12110
Country
United States
Facility Name
ImClone Investigational Site
City
Mineola
State/Province
New York
ZIP/Postal Code
11501
Country
United States
Facility Name
ImClone Investigational Site
City
New York
State/Province
New York
ZIP/Postal Code
10016
Country
United States
Facility Name
ImClone Investigational Site
City
Rexford
State/Province
New York
ZIP/Postal Code
12148
Country
United States
Facility Name
ImClone Investigational Site
City
Stony Brook
State/Province
New York
ZIP/Postal Code
11794
Country
United States
Facility Name
ImClone Investigational Site
City
Valhalla
State/Province
New York
ZIP/Postal Code
10595
Country
United States
Facility Name
ImClone Investigational Site
City
Durham
State/Province
North Carolina
ZIP/Postal Code
27710
Country
United States
Facility Name
ImClone Investigational Site
City
Greenville
State/Province
North Carolina
ZIP/Postal Code
27834
Country
United States
Facility Name
ImClone Investigational Site
City
High Point
State/Province
North Carolina
ZIP/Postal Code
27262
Country
United States
Facility Name
ImClone Investigational Site
City
Raleigh
State/Province
North Carolina
ZIP/Postal Code
27609
Country
United States
Facility Name
ImClone Investigational Site
City
Winston-Salem
State/Province
North Carolina
ZIP/Postal Code
27103
Country
United States
Facility Name
ImClone Investigational Site
City
Winston-Salem
State/Province
North Carolina
ZIP/Postal Code
27157
Country
United States
Facility Name
ImClone Investigational Site
City
Bismarck
State/Province
North Dakota
ZIP/Postal Code
58501
Country
United States
Facility Name
ImClone Investigational Site
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45267
Country
United States
Facility Name
ImClone Investigational Site
City
Cleveland
State/Province
Ohio
ZIP/Postal Code
44106
Country
United States
Facility Name
ImClone Investigational Site
City
Columbus
State/Province
Ohio
ZIP/Postal Code
43235
Country
United States
Facility Name
ImClone Investigational Site
City
Dayton
State/Province
Ohio
ZIP/Postal Code
45459
Country
United States
Facility Name
ImClone Investigational Site
City
Newark
State/Province
Ohio
ZIP/Postal Code
43055
Country
United States
Facility Name
ImClone Investigational Site
City
Oklahoma City
State/Province
Oklahoma
ZIP/Postal Code
73118
Country
United States
Facility Name
ImClone Investigational Site
City
Hershey
State/Province
Pennsylvania
ZIP/Postal Code
17033
Country
United States
Facility Name
ImClone Investigational Site
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19106
Country
United States
Facility Name
ImClone Investigational Site
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19107
Country
United States
Facility Name
ImClone Investigational Site
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19141-3098
Country
United States
Facility Name
ImClone Investigational Site
City
Pittsburgh
State/Province
Pennsylvania
ZIP/Postal Code
15232
Country
United States
Facility Name
ImClone Investigational Site
City
Greenville
State/Province
South Carolina
ZIP/Postal Code
29615
Country
United States
Facility Name
ImClone Investigational Site
City
Knoxville
State/Province
Tennessee
ZIP/Postal Code
37916
Country
United States
Facility Name
ImClone Investigational Site
City
Memphis
State/Province
Tennessee
ZIP/Postal Code
38120
Country
United States
Facility Name
ImClone Investigational Site
City
Nashville
State/Province
Tennessee
ZIP/Postal Code
37203
Country
United States
Facility Name
ImClone Investigational Site
City
Austin
State/Province
Texas
ZIP/Postal Code
78759
Country
United States
Facility Name
ImClone Investigational Site
City
Dallas
State/Province
Texas
ZIP/Postal Code
75230
Country
United States
Facility Name
ImClone Investigational Site
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
Facility Name
ImClone Investigational Site
City
Plano
State/Province
Texas
ZIP/Postal Code
75075
Country
United States
Facility Name
ImClone Investigational Site
City
Temple
State/Province
Texas
ZIP/Postal Code
76508
Country
United States
Facility Name
ImClone Investigational Site
City
Ogden
State/Province
Utah
ZIP/Postal Code
84403
Country
United States
Facility Name
ImClone Investigational Site
City
Arlington
State/Province
Virginia
ZIP/Postal Code
22205
Country
United States
Facility Name
ImClone Investigational Site
City
Danville
State/Province
Virginia
ZIP/Postal Code
24541
Country
United States
Facility Name
ImClone Investigational Site
City
Newport News
State/Province
Virginia
ZIP/Postal Code
23606
Country
United States
Facility Name
ImClone Investigational Site
City
Richmond
State/Province
Virginia
ZIP/Postal Code
23230
Country
United States
Facility Name
ImClone Investigational Site
City
Seattle
State/Province
Washington
ZIP/Postal Code
98104
Country
United States
Facility Name
ImClone Investigational Site
City
Spokane
State/Province
Washington
ZIP/Postal Code
99204
Country
United States
Facility Name
ImClone Investigational Site
City
Spokane
State/Province
Washington
ZIP/Postal Code
99218
Country
United States
Facility Name
ImClone Investigational Site
City
Walla Walla
State/Province
Washington
ZIP/Postal Code
99362
Country
United States
Facility Name
ImClone Investigational Site
City
Green Bay
State/Province
Wisconsin
ZIP/Postal Code
54301
Country
United States
Facility Name
ImClone Investigational Site
City
Madison
State/Province
Wisconsin
ZIP/Postal Code
53792
Country
United States
Facility Name
ImClone Investigational Site
City
Milwaukee
State/Province
Wisconsin
ZIP/Postal Code
53226
Country
United States
Facility Name
ImClone Investigational Site
City
Perth
State/Province
Australian Capital Territory
Country
Australia
Facility Name
ImClone Investigational Site
City
Sydney
State/Province
Australian Capital Territory
Country
Australia
Facility Name
ImClone Investigational Site
City
Sydney
State/Province
New South Wales
Country
Australia
Facility Name
ImClone Investigational Site
City
Wollongong
State/Province
New South Wales
Country
Australia
Facility Name
ImClone Investigational Site
City
South Brisbane
State/Province
Queensland
Country
Australia
Facility Name
ImClone Investigational Site
City
Adelaide
State/Province
South Australia
Country
Australia
Facility Name
ImClone Investigational Site
City
Wien
Country
Australia
Facility Name
ImClone Investigational Site
City
Graz
Country
Austria
Facility Name
ImClone Investigational Site
City
Salzburg
Country
Austria
Facility Name
ImClone Investigational Site
City
Wein
Country
Austria
Facility Name
ImClone Investigational Site
City
Wien
Country
Austria
Facility Name
ImClone Investigational Site
City
Charleroi
Country
Belgium
Facility Name
ImClone Investigational Site
City
Brno
Country
Czech Republic
Facility Name
ImClone Investigational Site
City
Olomouc
Country
Czech Republic
Facility Name
ImClone Investigational Site
City
Praha 5
Country
Czech Republic
Facility Name
ImClone Investigational Site
City
Helsinki
Country
Finland
Facility Name
ImClone Investigational Site
City
Avignon
Country
France
Facility Name
ImClone Investigational Site
City
Marseille
Country
France
Facility Name
ImClone Investigational Site
City
Nice
Country
France
Facility Name
ImClone Investigational Site
City
Saint Herblain
Country
France
Facility Name
ImClone Investigational Site
City
Aschaffenburg
Country
Germany
Facility Name
ImClone Investigational Site
City
Augsburg
Country
Germany
Facility Name
ImClone Investigational Site
City
Dessau
Country
Germany
Facility Name
ImClone Investigational Site
City
Dortmund
Country
Germany
Facility Name
ImClone Investigational Site
City
Essen
Country
Germany
Facility Name
ImClone Investigational Site
City
Hamburg
Country
Germany
Facility Name
ImClone Investigational Site
City
Hanburg
Country
Germany
Facility Name
ImClone Investigational Site
City
Kaiserslautern
Country
Germany
Facility Name
ImClone Investigational Site
City
Kassel
Country
Germany
Facility Name
ImClone Investigational Site
City
Magdeburg
Country
Germany
Facility Name
ImClone Investigational Site
City
Mainz
Country
Germany
Facility Name
ImClone Investigational Site
City
Mannheim
Country
Germany
Facility Name
ImClone Investigational Site
City
Muchnhen
Country
Germany
Facility Name
ImClone Investigational Site
City
Munchen
Country
Germany
Facility Name
ImClone Investigational Site
City
Regensburg
Country
Germany
Facility Name
ImClone Investigational Site
City
Saarbrucken
Country
Germany
Facility Name
ImClone Investigational Site
City
Stralsund
Country
Germany
Facility Name
ImClone Investigational Site
City
Stuttgart
Country
Germany
Facility Name
ImClone Investigational Site
City
Hong Kong
Country
Hong Kong
Facility Name
ImClone Investigational Site
City
Rozzano
State/Province
Milano
Country
Italy
Facility Name
ImClone Investigational Site
City
Ancona
Country
Italy
Facility Name
ImClone Investigational Site
City
Bergamo
Country
Italy
Facility Name
ImClone Investigational Site
City
Candiolo
Country
Italy
Facility Name
ImClone Investigational Site
City
Firenze
Country
Italy
Facility Name
ImClone Investigational Site
City
Genova
Country
Italy
Facility Name
ImClone Investigational Site
City
Livomo
Country
Italy
Facility Name
ImClone Investigational Site
City
Milano
Country
Italy
Facility Name
ImClone Investigational Site
City
Modena
Country
Italy
Facility Name
ImClone Investigational Site
City
Napoli
Country
Italy
Facility Name
ImClone Investigational Site
City
Perugia
Country
Italy
Facility Name
ImClone Investigational Site
City
Reggio Emilia
Country
Italy
Facility Name
ImClone Investigational Site
City
Roma
Country
Italy
Facility Name
ImClone Investigational Site
City
Rome
Country
Italy
Facility Name
ImClone Investigational Site
City
Apeldorn
Country
Netherlands
Facility Name
ImClone Investigational Site
City
Dordrecht
Country
Netherlands
Facility Name
ImClone Investigational Site
City
Montebello
State/Province
Oslo
Country
Norway
Facility Name
ImClone Investigational Site
City
Oslo
Country
Norway
Facility Name
ImClone Investigational Site
City
Porto
Country
Portugal
Facility Name
ImClone Investigational Site
City
Bratislava
Country
Slovakia
Facility Name
ImClone Investigational Site
City
Lund
Country
Sweden
Facility Name
ImClone Investigational Site
City
Stockholm
Country
Sweden
Facility Name
ImClone Investigational Site
City
Bern
Country
Switzerland
Facility Name
ImClone Investigational Site
City
Liestal
Country
Switzerland
Facility Name
ImClone Investigational Site
City
Zurich
Country
Switzerland
Facility Name
ImClone Investigational Site
City
Foresterhill
State/Province
Aberdeenshire
Country
United Kingdom
Facility Name
ImClone Investigational Site
City
Hull
State/Province
Avon
Country
United Kingdom
Facility Name
ImClone Investigational Site
City
Glasgow
State/Province
Central
Country
United Kingdom
Facility Name
ImClone Investigational Site
City
Poole
State/Province
Dorset
Country
United Kingdom
Facility Name
ImClone Investigational Site
City
London
State/Province
Greater London
Country
United Kingdom
Facility Name
ImClone Investigational Site
City
Bournemouth
State/Province
Hampshire
Country
United Kingdom
Facility Name
ImClone Investigational Site
City
Guildford
State/Province
Surrey
Country
United Kingdom
Facility Name
ImClone Investigational Site
City
Sutton
State/Province
Surrey
Country
United Kingdom

12. IPD Sharing Statement

Learn more about this trial

Study of Irinotecan and Cetuximab Versus Irinotecan as Second-Line Treatment in Patients With Metastatic, EGFR-Positive Colorectal Cancer

We'll reach out to this number within 24 hrs